Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8189717 | 1.00 | ACE (0.44) | ACESMN1; SMN2L3MBTL1POLBCYP2D6 | |
| SCHEMBL385463 | 0.80 | ACE (0.59) | ACESMN1; SMN2L3MBTL1POLBCYP2D6 | |
| SCHEMBL385403 | 0.80 | ACE (0.59) | ACESMN1; SMN2L3MBTL1POLBCYP2D6 | |
| SCHEMBL6141057 | 0.80 | ACE (0.59) | ACESMN1; SMN2L3MBTL1POLBCYP2D6 | |
| SCHEMBL12101103 | 0.77 | ACE (0.40) | ACESMN1; SMN2L3MBTL1POLBCYP2D6 | |
| SCHEMBL386486 | 0.77 | ACE (0.61) | ACEAPEX1TSHRCYP3A4TDP1 | |
| SCHEMBL15198795 | 0.77 | MMP1 (0.39) | SMN1; SMN2L3MBTL1KMT2ATSHRTDP1 | |
| SCHEMBL385803 | 0.77 | ACE (0.61) | ACEAPEX1TSHRCYP3A4TDP1 | |
| SCHEMBL386126 | 0.77 | ACE (0.61) | ACEAPEX1TSHRCYP3A4TDP1 | |
| Hydrochloric Acid SCHEMBL11148459 | 0.76 | ACE (0.59) | ACEAPEX1TSHRCYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9061069-B2 | Use of constrained peptide mimic oligomers as vectorization agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-06-23 | — | — | US | disclosed |
| US-9061069-B2 | Use of constrained peptide mimic oligomers as vectorization agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-06-23 | — | — | US | disclosed |
| US-20120184480-A1 | USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS | UNIVERSITE DE MONTPELLIER I (FR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184480-A1 | USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS | UNIVERSITE DE MONTPELLIER I (FR) | 2012-07-19 | — | — | US | disclosed |
| US-7179907-B2 | Antibiotic compounds | SOMALOGIC OPERATING CO. INC. | 2007-02-20 | — | — | US | disclosed |
| EP-0413762-B1 | PEPTIDE ANALOGS AND THEIR USE AS HAPTENS TO ELICIT CATALYTIC ANTIBODIES | IGEN INT INC (US) | 2000-07-12 | — | — | EP | disclosed |
| EP-0413762-A4 | PEPTIDE ANALOGS AND THEIR USE AS HAPTENS TO ELICIT CATALYTIC ANTIBODIES | — | 1992-01-15 | — | — | EP | disclosed |
| EP-0413762-A1 | PEPTIDE ANALOGS AND THEIR USE AS HAPTENS TO ELICIT CATALYTIC ANTIBODIES | IGEN, INCORPORATED (US) | 1991-02-27 | — | — | EP | disclosed |
| WO-1989010961-A1 | PEPTIDE ANALOGS AND THEIR USE AS HAPTENS TO ELICIT CATALYTIC ANTIBODIES | IGEN, INC. (US) | 1989-11-16 | — | — | WO | disclosed |
| US-4595532-A | N-(substituted-methyl)-azetidin-2-ones | UNIVERSITY OF NOTRE DAME DU LAC (US) | 1986-06-17 | — | — | US | disclosed |
| EP-0116432-A2 | Improvements in or relating to N-(substituted-methyl)-azetidin-2-ones | THE UNIVERSITY OF NOTRE DAME DU LAC (US) | 1984-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184480-A1 | USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS | DNPEP, IAPP, VIP | ACE 167/4885SMN1; SMN2 2267/4885L3MBTL1 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.